Skip to main content

Novo Nordisk's Wegovy shows heart benefits beyond weight loss, new data suggests

By The Wall Street Journal  
   November 17, 2023

The effectiveness of Novo Nordisk's blockbuster obesity treatment Wegovy in reducing heart attacks and strokes could be due to more than weight loss alone, according to new clinical trial data.

Full story

Get the latest on healthcare leadership in your inbox.